Zepbound vs Wegovy, without the medical-school vocabulary
Two of the most-discussed GLP-1 medications, compared the way people actually ask about them.
These two get compared constantly, and for good reason — they're currently the two medications most specifically approved for chronic weight management, rather than for diabetes with weight change as a secondary effect. Here's what actually differs.
The core difference: what's actually in them
- Zepbound's active ingredient is tirzepatide, which acts on two gut hormone pathways (GLP-1 and GIP).
- Wegovy's active ingredient is semaglutide, which acts on the GLP-1 pathway.
- Both are made as prefilled injector pens, dosed weekly, with doses increased gradually over time.
In normal English
Dual vs single agonist
Tirzepatide is often described as a "dual" agonist because it acts on two hormone receptor pathways instead of one. What that means for outcomes, for any individual person, is a clinical question — not something we'll generalize here.
Approval and manufacturer
Zepbound is made by Eli Lilly and is approved for chronic weight management. Its diabetes-approved sibling (same active ingredient, different brand and approval) is Mounjaro. Wegovy is made by Novo Nordisk and is also approved for chronic weight management, plus a cardiovascular risk reduction indication in certain adults; its diabetes-approved sibling is Ozempic.
Worth knowing
Because Zepbound and Mounjaro share an ingredient, and Wegovy and Ozempic share an ingredient, some of what you read about "Ozempic" in the news is really about semaglutide broadly — including Wegovy.
Cost and insurance differences
Both are typically expensive without insurance, and both manufacturers offer savings programs with their own eligibility rules. Which one your insurance prefers — if either — often comes down to formulary contracts your employer or plan has negotiated, not a clinical judgment about which drug is better for you personally.
Why this matters
This is why two people can have very similar health situations and get very different advice about which medication to pursue: the deciding factor is sometimes their specific insurance plan's formulary, not a universal clinical recommendation.
So which one is 'better'?
We're not going to answer that here, and you should be skeptical of any source that answers it with certainty for you personally. Individual response to medication varies, both drugs have their own dosing schedules and side effect profiles, and the right choice depends on your health history, your insurance, and your prescribing clinician's judgment.
The awkward question
Can I just ask my doctor for whichever one is cheaper?
You can absolutely bring cost into the conversation — it's a completely reasonable thing to prioritize, and many clinicians appreciate knowing your constraints up front so they can prescribe accordingly.
Sources & references
A note on this article: This site is for general information only. It isn't medical advice, and it doesn't replace a conversation with a qualified healthcare professional who knows your health history. Always talk to a doctor or pharmacist before starting, stopping, or changing any medication.
This one doesn't have a named medical reviewer yet. We're careful about sourcing either way — just treat anything specific to your own health as a starting point for a conversation with your doctor or pharmacist, not the final word.
Related reading
What are GLP-1s, actually?
Before comparing brand names or arguing about price, it helps to know what this whole category of medication actually is.
6 min readCostThe strange economics of a $1,000 medication
The list price on a GLP-1 and the price you'll actually pay can be wildly different numbers. Here's why.
8 min read